| MDL | MFCD19441262 |
|---|---|
| Molecular Weight | 475.95 |
| Molecular Formula | C21H22ClN5O4S |
| SMILES | COC1=CC2=C(C=C1OC)C(N(CC)CC)=NC3=C(S(=O)(C4=CC=C(Cl)C=C4)=O)N=NN32 |
Targocil functions as a bacteriostatic inhibitor of wall teichoic acid (WTA) biosynthesis which can inhibit the growth of methicillin-susceptible S. aureus ( MSSA ) and methicillin-resistant S. aureus ( MRSA ) with MIC 90 s of 2 μg/ mL for both MRSA and MSSA.
MIC90: 2 μg/mL (MSSA), 2 μg/mL (MRSA) [1]
MICs of Targocil against S. aureus strains Newman, MW2, MG2375, and MG2389 are 1 μg/mL for all strains. Targocil shows excellent activity against S. aureus isolates from suspected cases of bacterial keratitis, including both MSSA and MRSA isolates, with MICs that range from 1 to 2 μg/ mL. Targocil, a derivative of 1835F03, exhibits better activity against all keratitis isolates than the original lead compound, 1835F03. Bovine serum exhibits a detectable but moderate inhibitory effect on the in vitro antimicrobial activities of both 1835F03 and Targocil, increasing the MICs of both by 4- to 8-fold. Compare to the vehicle alone, Targocil at 5 μg/mL exhibits little toxicity for HCECs, even after 24 h of exposure. However, 40 μg/mL Targocil shows toxicity at all time points tested. Targocil at levels equal to 10×MIC in vitro readily inhibits growth of Newman and MG2375 in the presence of HCECs [1]
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Solid
Room temperature in continental US; may vary elsewhere.
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
DMSO : 33.33 mg/mL ( 70.03 mM ; Need ultrasonic)
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.1011 mL | 10.5053 mL | 21.0106 mL |
| 5 mM | 0.4202 mL | 2.1011 mL | 4.2021 mL |
| 10 mM | 0.2101 mL | 1.0505 mL | 2.1011 mL |
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (5.25 mM); Clear solution